Pub Date : 2026-02-01Epub Date: 2026-01-21DOI: 10.1177/08927790251412401
Juan Fulla, Juan Sebastian Arroyave, Francisca Larenas, Steven A Kaplan, Michael Palese, Catherine Sanchez
Purpose: To evaluate outcomes after water vapor thermal therapy (WVTT) for benign prostatic hyperplasia (BPH), stratified by varying degrees of median lobe (ML) protrusion.
Patients and methods: We enrolled men aged ≥45 years with BPH who underwent WVTT from July 2020 to September 2023. Inclusion criteria were an estimated prostate volume of 30-80 cc, International Prostate Symptom Score (IPSS) ≥12, and maximum urinary flow rate <16 mL/sec. ML protrusion was assessed using ultrasound (with bladder volume ≥250 cc) and flexible cystoscopy; the average of both measurements was used to classify ML protrusion into <5 mm, 5-10 mm, and >10 mm. Primary outcomes included postoperative complications such as surgical retreatment, acute urinary retention (AUR), and urinary tract infections (UTIs).
Results: With a median follow-up of 29.1 months (range: 24-36), improvements in lower urinary tract symptoms (LUTS) were similar across all groups, with consistent symptom reduction (Δ = -13) in both obstructive and irritative IPSS components. Rates of AUR and UTIs showed no significant variation across groups: AUR (no ML 9.5%; <5 mm 8.7%; 5-10 mm 12%; >10 mm 17%; p = 0.7) and UTI (no ML 8.4%; <5 mm 4.3%; 5-10 mm 9.3%; >10 mm 8.3%; p = 0.8). Despite comparable preoperative characteristics, surgical retreatment rates varied significantly with ML protrusion: no ML (3.2%), <5 mm (4.3%), 5-10 mm (14%), and >10 mm (21%) (p = 0.007), highlighting increased retreatment risk associated with greater ML protrusion.
Conclusions: WVTT effectively relieves LUTS across all ML configurations. However, patients with greater ML protrusion may face a higher risk of retreatment, likely because of increased bladder neck and urethral involvement. These findings suggest that detailed ML assessment can aid in patient counseling and stratification.
目的:评价水蒸汽热疗法(WVTT)治疗良性前列腺增生(BPH)的疗效,以不同程度的正中叶(ML)突出分层。患者和方法:我们招募了年龄≥45岁的BPH患者,他们在2020年7月至2023年9月期间接受了WVTT。纳入标准为估计前列腺体积30- 80cc,国际前列腺症状评分(IPSS)≥12,最大尿流率10mm。主要结局包括术后并发症,如手术再治疗、急性尿潴留(AUR)和尿路感染(uti)。结果:中位随访29.1个月(范围:24-36),各组下尿路症状(LUTS)的改善相似,阻塞性和刺激性IPSS成分的症状减轻一致(Δ = -13)。AUR和UTI的发生率各组间无显著差异:AUR(无ML 9.5%; 10 mm 17%; p = 0.7)和UTI(无ML 8.4%; 10 mm 8.3%; p = 0.8)。尽管术前特征相似,但ML突出的手术再治疗率差异显著:无ML (3.2%), 10 mm (21%) (p = 0.007),突出了ML突出增加的再治疗风险。结论:WVTT有效地缓解了所有ML配置中的LUTS。然而,ML突出较大的患者可能面临更高的再治疗风险,可能是因为膀胱颈部和尿道受累增加。这些发现表明,详细的ML评估有助于患者咨询和分层。
{"title":"Impact of Median Lobe Protrusion on Outcomes of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Prospective Analysis.","authors":"Juan Fulla, Juan Sebastian Arroyave, Francisca Larenas, Steven A Kaplan, Michael Palese, Catherine Sanchez","doi":"10.1177/08927790251412401","DOIUrl":"https://doi.org/10.1177/08927790251412401","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate outcomes after water vapor thermal therapy (WVTT) for benign prostatic hyperplasia (BPH), stratified by varying degrees of median lobe (ML) protrusion.</p><p><strong>Patients and methods: </strong>We enrolled men aged ≥45 years with BPH who underwent WVTT from July 2020 to September 2023. Inclusion criteria were an estimated prostate volume of 30-80 cc, International Prostate Symptom Score (IPSS) ≥12, and maximum urinary flow rate <16 mL/sec. ML protrusion was assessed using ultrasound (with bladder volume ≥250 cc) and flexible cystoscopy; the average of both measurements was used to classify ML protrusion into <5 mm, 5-10 mm, and >10 mm. Primary outcomes included postoperative complications such as surgical retreatment, acute urinary retention (AUR), and urinary tract infections (UTIs).</p><p><strong>Results: </strong>With a median follow-up of 29.1 months (range: 24-36), improvements in lower urinary tract symptoms (LUTS) were similar across all groups, with consistent symptom reduction (Δ = -13) in both obstructive and irritative IPSS components. Rates of AUR and UTIs showed no significant variation across groups: AUR (no ML 9.5%; <5 mm 8.7%; 5-10 mm 12%; >10 mm 17%; <i>p</i> = 0.7) and UTI (no ML 8.4%; <5 mm 4.3%; 5-10 mm 9.3%; >10 mm 8.3%; <i>p</i> = 0.8). Despite comparable preoperative characteristics, surgical retreatment rates varied significantly with ML protrusion: no ML (3.2%), <5 mm (4.3%), 5-10 mm (14%), and >10 mm (21%) (<i>p</i> = 0.007), highlighting increased retreatment risk associated with greater ML protrusion.</p><p><strong>Conclusions: </strong>WVTT effectively relieves LUTS across all ML configurations. However, patients with greater ML protrusion may face a higher risk of retreatment, likely because of increased bladder neck and urethral involvement. These findings suggest that detailed ML assessment can aid in patient counseling and stratification.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":"40 2","pages":"205-211"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-19DOI: 10.1177/08927790251400302
Loris Cacciatore, Antonio Minore, Pierangelo Contessa, Alberto Ragusa, Arianna Pischetola, Lilla Bonanno, Luca Cindolo, Annamaria Salerno, Francesco Esperto, Antonio Rosario Iannello, Rocco Papalia
Background: The flexible and navigable suction sheath (FANS) is designed for the effective treatment of renal stones of various sizes. This study aimed to assess and compare the safety and postoperative outcomes at 30 days following FANS treatment for stones smaller and larger than 20 mm.
Materials and methods: From January to December 2024, patients undergoing retrograde intrarenal surgery performed with FANS were prospectively recruited and divided into two groups based on stone diameter (Group 1: DMAX <20 mm, Group 2: DMAX ≥20 mm). Baseline, perioperative, and follow-up characteristics were analyzed. Stone-free rate (SFR) was evaluated with a non-contrast CT scan at 1-month. Statistical analysis was performed using the unpaired Student's t-test and chi-squared test with Yates' correction.
Results: A total of 140 patients were enrolled, with 77 having stones <20 mm and 63 having stones ≥20 mm. While a significant difference in stone diameters was observed, no discrepancies were noted regarding the mean stone density between the two groups, thus minimizing the potential for bias. No major Clavien-Dindo complications occurred in either group without differences in hospital length of stay, but Group 1 reported lower visual analogue scale pain. No significant differences in Grade A, B, and C SFR (all p > 0.05) and re-intervention (p = 0.58) were observed, suggesting similar efficacy for both stone sizes.
Conclusions: This study demonstrates that the FANS as a valuable tool for enhancing patient safety and outcomes in managing larger stones, achieving adequate SFR, and reducing the need for re-intervention without major complications. In the future, FANS may effectively change the indications for stone's treatment according to diameter.
{"title":"Will Flexible and Navigable Suction Sheaths Change the Paradigm of Stone Treatment in the Era of Novel Generation Lasers?","authors":"Loris Cacciatore, Antonio Minore, Pierangelo Contessa, Alberto Ragusa, Arianna Pischetola, Lilla Bonanno, Luca Cindolo, Annamaria Salerno, Francesco Esperto, Antonio Rosario Iannello, Rocco Papalia","doi":"10.1177/08927790251400302","DOIUrl":"10.1177/08927790251400302","url":null,"abstract":"<p><strong>Background: </strong>The flexible and navigable suction sheath (FANS) is designed for the effective treatment of renal stones of various sizes. This study aimed to assess and compare the safety and postoperative outcomes at 30 days following FANS treatment for stones smaller and larger than 20 mm.</p><p><strong>Materials and methods: </strong>From January to December 2024, patients undergoing retrograde intrarenal surgery performed with FANS were prospectively recruited and divided into two groups based on stone diameter (Group 1: DMAX <20 mm, Group 2: DMAX ≥20 mm). Baseline, perioperative, and follow-up characteristics were analyzed. Stone-free rate (SFR) was evaluated with a non-contrast CT scan at 1-month. Statistical analysis was performed using the unpaired Student's <i>t</i>-test and chi-squared test with Yates' correction.</p><p><strong>Results: </strong>A total of 140 patients were enrolled, with 77 having stones <20 mm and 63 having stones ≥20 mm. While a significant difference in stone diameters was observed, no discrepancies were noted regarding the mean stone density between the two groups, thus minimizing the potential for bias. No major Clavien-Dindo complications occurred in either group without differences in hospital length of stay, but Group 1 reported lower visual analogue scale pain. No significant differences in Grade A, B, and C SFR (all <i>p</i> > 0.05) and re-intervention (<i>p</i> = 0.58) were observed, suggesting similar efficacy for both stone sizes.</p><p><strong>Conclusions: </strong>This study demonstrates that the FANS as a valuable tool for enhancing patient safety and outcomes in managing larger stones, achieving adequate SFR, and reducing the need for re-intervention without major complications. In the future, FANS may effectively change the indications for stone's treatment according to diameter.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"158-163"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145604393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-06DOI: 10.1177/08927790251405794
Noah Swärd, Anthony Galvez, Riley Hull, Joseph Girgiss, Jonathan Katz, Jake L Roberts, Tyler Sheetz, Luke K Griffiths, Martin Ugander, Roger L Sur
Introduction and objective: Percutaneous nephrolithotomy percutaneous nephrostomy (PCNL) is a minimally invasive procedure for kidney stone removal traditionally guided by fluoroscopy. This study aimed to evaluate the feasibility and outcomes of radiation-free PCNL using ultrasonography alone compared with standard fluoroscopy-guided PCNL.
Methods: A total of 63 PCNL cases were eligible for radiation-free PCNL, but 27 were excluded (intraoperatively aborted, ureteroscopy performed instead, preoperative complex anatomy). Of the remaining 36 cases eligible for radiation-free PCNL, 11 were converted intraoperatively to fluoroscopic-based PCNL. Postoperative computed tomography (CT) imaging was available for only 16 of the 25 radiation-free PCNL cases and 4 of the 11 converted cases. We designated these 16 prospective radiation-free PCNL cases (2024-2025) as Group A. For comparison purposes, we identified a historical case-matched cohort of 150 PCNLs. Of these, 67 were excluded (similar reasons), leaving 83 retrospective fluoroscopy-guided PCNL cases (2022-2024) called Group B. A subset of Group A cases was converted from radiation-free intraoperatively to fluoroscopy and were designated as Group C. The primary outcome was stone-free rate (SFR), assessed postoperatively by noncontrast CT (2-3 mm slices). Secondary outcomes included estimated blood loss, complication rates (Clavien-Dindo), and postoperative stone events.
Results: The median preoperative stone burden was 35 mm in Group A and 27 mm in Groups B and C [p = 0.3]. SFR (Grade A) was comparable across Groups A, B, and C [38%, 30%, and 25%, respectively (p = 0.8)]. No differences were observed in complications or secondary outcomes.
Conclusions: Radiation-free PCNL is feasible and yields comparable outcomes to standard fluoroscopy-guided PCNL, offering a promising method to reduce radiation exposure without compromising surgical success. However, we identified a consistent theme of poor visualization that prompted conversion to fluoroscopy for some of the cases. Innovation directed toward improving tool echogenicity is key to diffusing this technique.
{"title":"Factors Associated with a Higher Risk of Conversion from Radiation-Free Percutaneous Nephrolithotomy (PCNL) to Fluoroscopy-Guided Percutaneous Nephrolithotomy.","authors":"Noah Swärd, Anthony Galvez, Riley Hull, Joseph Girgiss, Jonathan Katz, Jake L Roberts, Tyler Sheetz, Luke K Griffiths, Martin Ugander, Roger L Sur","doi":"10.1177/08927790251405794","DOIUrl":"10.1177/08927790251405794","url":null,"abstract":"<p><strong>Introduction and objective: </strong>Percutaneous nephrolithotomy percutaneous nephrostomy (PCNL) is a minimally invasive procedure for kidney stone removal traditionally guided by fluoroscopy. This study aimed to evaluate the feasibility and outcomes of radiation-free PCNL using ultrasonography alone compared with standard fluoroscopy-guided PCNL.</p><p><strong>Methods: </strong>A total of 63 PCNL cases were eligible for radiation-free PCNL, but 27 were excluded (intraoperatively aborted, ureteroscopy performed instead, preoperative complex anatomy). Of the remaining 36 cases eligible for radiation-free PCNL, 11 were converted intraoperatively to fluoroscopic-based PCNL. Postoperative computed tomography (CT) imaging was available for only 16 of the 25 radiation-free PCNL cases and 4 of the 11 converted cases. We designated these 16 prospective radiation-free PCNL cases (2024-2025) as Group A. For comparison purposes, we identified a historical case-matched cohort of 150 PCNLs. Of these, 67 were excluded (similar reasons), leaving 83 retrospective fluoroscopy-guided PCNL cases (2022-2024) called Group B. A subset of Group A cases was converted from radiation-free intraoperatively to fluoroscopy and were designated as Group C. The <i>primary outcome</i> was stone-free rate (SFR), assessed postoperatively by noncontrast CT (2-3 mm slices). <i>Secondary outcomes</i> included estimated blood loss, complication rates (Clavien-Dindo), and postoperative stone events.</p><p><strong>Results: </strong>The median preoperative stone burden was 35 mm in Group A and 27 mm in Groups B and C [p = 0.3]. SFR (Grade A) was comparable across Groups A, B, and C [38%, 30%, and 25%, respectively (p = 0.8)]. No differences were observed in complications or secondary outcomes.</p><p><strong>Conclusions: </strong>Radiation-free PCNL is feasible and yields comparable outcomes to standard fluoroscopy-guided PCNL, offering a promising method to reduce radiation exposure without compromising surgical success. However, we identified a consistent theme of poor visualization that prompted conversion to fluoroscopy for some of the cases. Innovation directed toward improving tool echogenicity is key to diffusing this technique.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"146-157"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-06DOI: 10.1177/08927790251392896
Vineet Gauhar, Ee Jean Lim, Bhaskar Kumar Somani, Jaisukh Kalathia, Edgar Beltrán-Suárez, Gadzhiev Nariman, Mahmoud Laymon, Kremena Petkova, Esteban Acuna, Mohamed Amine Lakmichi, Khi Yung Fong, Marek Zawadzki, Nitesh Kumar, Amish Mehta, Roy Zen Sing Teng, Gopal Ramdas Tak, Alexey G Martov, Marcos Cepeda, Vigen Malkhasyan, Arun Chawla, Daniele Castellani, Thomas R W Herrmann, Steffi Kar Kei Yuen
Background: Renal stones in anomalous kidneys pose surgical challenges due to altered anatomy. Miniaturized percutaneous nephrolithotomy (mini-PCNL) reduces morbidity, but concerns remain about stone-free rates (SFRs) and infection. Suction-assisted mini-PCNL (SM-PCNL) enhances fragment removal and controls intrarenal pressure, but its role in anomalous kidneys is unclear.
Objective: To evaluate perioperative outcomes of SM-PCNL in anomalous kidneys in a multicenter, real-world study and assess variations based on positioning, lithotripsy modality, and renal anomalies.
Methodology: This prospective study across 15 centers (January-December 2024) included 287 adults undergoing SM-PCNL for renal stones in anomalous kidneys. Patients with normal anatomy, non-suction PCNL, or incomplete data were excluded. SFR was assessed via a 30-day non-contrast CT: 100% stone-free (Grade A), residual fragments ≤4 mm (Grade B), or >4 mm/multiple (Grade C, requiring reintervention).
Results: Malrotation (65.5%) was the most common anomaly, followed by duplex systems (25.1%), horseshoe kidneys (8.4%), and ectopic kidneys (1.0%). Median stone size was 1.7 cm. Supine positioning was used in 54.4%. Lithotripsy was performed with holmium laser (50.9%), thulium fiber laser (11.1%), or pneumatic lithotripsy (26.1%). Intraoperative clearance was 95.4%. At 30 days, 93.4% achieved Grade A, 5.6% Grade B, and 1.0% required reintervention. Complications were low; 0.7% had sepsis requiring intensive care unit admission. No transfusions or pleural injuries occurred.
Conclusion: SM-PCNL using 18F suction sheaths with laser in a single stage achieved 93.4% complete SFR with negligible complications and minimal reintervention.
{"title":"Suction-Assisted Miniaturized Percutaneous Nephrolithotomy Outcomes in Anomalous Kidneys: A Multicenter Prospective Study-An EAU-Endourology Collaboration.","authors":"Vineet Gauhar, Ee Jean Lim, Bhaskar Kumar Somani, Jaisukh Kalathia, Edgar Beltrán-Suárez, Gadzhiev Nariman, Mahmoud Laymon, Kremena Petkova, Esteban Acuna, Mohamed Amine Lakmichi, Khi Yung Fong, Marek Zawadzki, Nitesh Kumar, Amish Mehta, Roy Zen Sing Teng, Gopal Ramdas Tak, Alexey G Martov, Marcos Cepeda, Vigen Malkhasyan, Arun Chawla, Daniele Castellani, Thomas R W Herrmann, Steffi Kar Kei Yuen","doi":"10.1177/08927790251392896","DOIUrl":"10.1177/08927790251392896","url":null,"abstract":"<p><strong>Background: </strong>Renal stones in anomalous kidneys pose surgical challenges due to altered anatomy. Miniaturized percutaneous nephrolithotomy (mini-PCNL) reduces morbidity, but concerns remain about stone-free rates (SFRs) and infection. Suction-assisted mini-PCNL (SM-PCNL) enhances fragment removal and controls intrarenal pressure, but its role in anomalous kidneys is unclear.</p><p><strong>Objective: </strong>To evaluate perioperative outcomes of SM-PCNL in anomalous kidneys in a multicenter, real-world study and assess variations based on positioning, lithotripsy modality, and renal anomalies.</p><p><strong>Methodology: </strong>This prospective study across 15 centers (January-December 2024) included 287 adults undergoing SM-PCNL for renal stones in anomalous kidneys. Patients with normal anatomy, non-suction PCNL, or incomplete data were excluded. SFR was assessed via a 30-day non-contrast CT: 100% stone-free (Grade A), residual fragments ≤4 mm (Grade B), or >4 mm/multiple (Grade C, requiring reintervention).</p><p><strong>Results: </strong>Malrotation (65.5%) was the most common anomaly, followed by duplex systems (25.1%), horseshoe kidneys (8.4%), and ectopic kidneys (1.0%). Median stone size was 1.7 cm. Supine positioning was used in 54.4%. Lithotripsy was performed with holmium laser (50.9%), thulium fiber laser (11.1%), or pneumatic lithotripsy (26.1%). Intraoperative clearance was 95.4%. At 30 days, 93.4% achieved Grade A, 5.6% Grade B, and 1.0% required reintervention. Complications were low; 0.7% had sepsis requiring intensive care unit admission. No transfusions or pleural injuries occurred.</p><p><strong>Conclusion: </strong>SM-PCNL using 18F suction sheaths with laser in a single stage achieved 93.4% complete SFR with negligible complications and minimal reintervention.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"164-171"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-14DOI: 10.1177/08927790251412815
Francesco Prata, Riccardo Mastroianni, Giuseppe Simone, Francesco Tedesco, Umberto Anceschi, Alberto Ragusa, Angelo Civitella, Aldo Brassetti, Alfredo Maria Bove, Andrea Iannuzzi, Alfredo Travino, Alessandro De Giuseppe, Marco Fantozzi, Mariavittoria Vescovo, Simone D'Annunzio, Mariaconsiglia Ferriero, Rocco Simone Flammia, Salvatore Guaglianone, Leonardo Misuraca, Flavia Proietti, Gabriele Tuderti, Costantino Leonardo, Giuseppe Perrone, Roberto Mario Scarpa, Rocco Papalia
Purpose: To report the first multicentric comparison between Hugo™ robot-assisted surgery/system (RAS) and Da Vinci® Xi for robot-assisted partial nephrectomy (RAPN).
Methods: Between October 2022 and March 2024, a total of 258 patients underwent off-clamp RAPN (Hugo RAS = 52 patients, and Da Vinci = 206 patients). Da Vinci and Hugo cases were matched in a 1:1 ratio using propensity score matching (PSM), adjusting for the Radius Exophytic Nearness Anterior Location score and renorrhaphy technique. Trifecta was defined as the coexistence of negative surgical margin status, no Clavien-Dindo grade ≥ 3 complications, and ≤ 30% estimated glomerular filtration rate (eGFR) reduction at discharge.
Results: After 1:1 PSM, two comparable populations of 52 patients each were selected. No intraoperative blood transfusion occurred in any group. The Hugo cohort displayed a higher rate of postoperative transfusions (7.7% vs 0%, p = 0.04). Nevertheless, perioperative complications were comparable (p = 0.32). The median length of stay (LOS) was shorter in the Da Vinci group (2 days vs 3 days, p < 0.001), as for median eGFR at discharge (74.5 mL/min/1.73m2vs 87.3 mL/min/1.73m2, p = 0.03). No significant difference in positive surgical margins was shown between the two groups (p = 0.08). Finally, a comparable Trifecta rate was achieved for both platforms (88.5% in the Hugo RAS group and 90.4% in the Da Vinci group, p = 0.75).
Conclusions: Despite the hierarchical role of Da Vinci in the robotic surgical landscape, RAPN can be safely carried out with the new Hugo RAS System, with satisfactory perioperative surgical outcomes comparable to the Da Vinci Xi System.
目的:报道Hugo™机器人辅助手术/系统(RAS)与Da Vinci®Xi在机器人辅助部分肾切除术(RAPN)中的首次多中心比较。方法:2022年10月至2024年3月,共258例患者接受了脱钳RAPN (Hugo RAS = 52例,Da Vinci = 206例)。Da Vinci和Hugo病例采用倾向评分匹配(PSM)按1:1比例匹配,调整桡骨外植性近前位评分和再缝合技术。三氟替尼的定义是:伴有手术切界阴性状态,无Clavien-Dindo分级≥3级并发症,出院时估计肾小球滤过率(eGFR)降低≤30%。结果:1:1 PSM后,选择了两个可比较的人群,每个人群52例患者。两组均未发生术中输血。Hugo队列显示出更高的术后输血率(7.7% vs 0%, p = 0.04)。然而,围手术期并发症具有可比性(p = 0.32)。达芬奇组的中位住院时间(LOS)较短(2天vs 3天,p < 0.001),而出院时的中位eGFR (74.5 mL/min/1.73m2 vs 87.3 mL/min/1.73m2, p = 0.03)。两组间阳性切缘差异无统计学意义(p = 0.08)。最后,两种治疗平台的triecta发生率相当(Hugo RAS组为88.5%,Da Vinci组为90.4%,p = 0.75)。结论:尽管达芬奇在机器人手术领域具有等级作用,但新的Hugo RAS系统可以安全地进行RAPN,其围手术期手术效果与达芬奇Xi系统相当。
{"title":"Hugo<sup>TM</sup> RAS <i>vs</i> Da Vinci® Xi Robot-Assisted Partial Nephrectomy: First Propensity Score-Matched Comparison of Perioperative and Functional Outcomes.","authors":"Francesco Prata, Riccardo Mastroianni, Giuseppe Simone, Francesco Tedesco, Umberto Anceschi, Alberto Ragusa, Angelo Civitella, Aldo Brassetti, Alfredo Maria Bove, Andrea Iannuzzi, Alfredo Travino, Alessandro De Giuseppe, Marco Fantozzi, Mariavittoria Vescovo, Simone D'Annunzio, Mariaconsiglia Ferriero, Rocco Simone Flammia, Salvatore Guaglianone, Leonardo Misuraca, Flavia Proietti, Gabriele Tuderti, Costantino Leonardo, Giuseppe Perrone, Roberto Mario Scarpa, Rocco Papalia","doi":"10.1177/08927790251412815","DOIUrl":"https://doi.org/10.1177/08927790251412815","url":null,"abstract":"<p><strong>Purpose: </strong>To report the first multicentric comparison between Hugo™ robot-assisted surgery/system (RAS) and Da Vinci® Xi for robot-assisted partial nephrectomy (RAPN).</p><p><strong>Methods: </strong>Between October 2022 and March 2024, a total of 258 patients underwent off-clamp RAPN (Hugo RAS = 52 patients, and Da Vinci = 206 patients). Da Vinci and Hugo cases were matched in a 1:1 ratio using propensity score matching (PSM), adjusting for the Radius Exophytic Nearness Anterior Location score and renorrhaphy technique. Trifecta was defined as the coexistence of negative surgical margin status, no Clavien-Dindo grade ≥ 3 complications, and ≤ 30% estimated glomerular filtration rate (eGFR) reduction at discharge.</p><p><strong>Results: </strong>After 1:1 PSM, two comparable populations of 52 patients each were selected. No intraoperative blood transfusion occurred in any group. The Hugo cohort displayed a higher rate of postoperative transfusions (7.7% <i>vs</i> 0%, <i>p</i> = 0.04). Nevertheless, perioperative complications were comparable (<i>p</i> = 0.32). The median length of stay (LOS) was shorter in the Da Vinci group (2 days <i>vs</i> 3 days, <i>p</i> < 0.001), as for median eGFR at discharge (74.5 mL/min/1.73m<sup>2</sup> <i>vs</i> 87.3 mL/min/1.73m<sup>2</sup>, <i>p</i> = 0.03). No significant difference in positive surgical margins was shown between the two groups (<i>p</i> = 0.08). Finally, a comparable Trifecta rate was achieved for both platforms (88.5% in the Hugo RAS group and 90.4% in the Da Vinci group, <i>p</i> = 0.75).</p><p><strong>Conclusions: </strong>Despite the hierarchical role of Da Vinci in the robotic surgical landscape, RAPN can be safely carried out with the new Hugo RAS System, with satisfactory perioperative surgical outcomes comparable to the Da Vinci Xi System.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":"40 2","pages":"181-187"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: This study aimed to evaluate the feasibility and safety of patients undergoing holmium laser enucleation of prostate (HoLEP), under transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter (SC) and sedoanalgesia.
Materials and methods: We retrospectively analyzed data of patients affected by benign prostatic obstruction candidate to HoLEP under TUIA using SC, from November 2023 to May 2024.
Results: A total of 50 patients were enrolled, median age 67 years; 14% were ASA ≥ 3, 2% and 22% had anticoagulation and antiplatelet drug therapy; 60% received alpha blockers, and 22% had both alpha blockers and 5α-reductase inhibitors; and 18% with an indwelling catheter. Preoperative median International Prostate Symptom Score (IPSS) and IPSS-quality of life (IPSS-QoL) were 16 (IQR: 11-21) and 4 (IQR: 4-6), median Qmax 10 mL/sec (IQR 3-19), median postvoid residual (PVR) 79 mL (IQR: 0-500). The median prostate volume was 50 mL (IQR 41-70 cc). Median preoperative Prostate Specific Antigen (PSA) was 1,70 (IQR 1,1-2,95). A prostate volume ≥ 80 mL was present in 10% of patients. The median enucleation time was 13,6 minutes (IQR 11,15-21,45) and the median morcellation time was 8,3 minutes (IQR 4,2-10,8). The median enucleated weight was 33 g (IQR 19,50-50). Median pain numeric rating scale before surgical procedure, at SC insertion, during enucleation, during morcellation, 2-hours postoperatively, on day 1 and 2 were 1 (0-3), 5 (2-6), 5 (3-7), 7 (5-10), 2 (1-4), 2 (1-4), and 3 (2-6). During enucleation, 10% required to start the target-controlled infusion with propofol. During morcellation, a half needs to get started propofol administration. The catheter was removed within 2 days in 100% of patients, and all were discharged within 48 hours. IPSS, IPSS-QoL, Qmax, and PVR showed significant improvement at 3 months.
Conclusions: TUIA with sedoanalgesia in HoLEP of small/medium prostate volume offers good pain control, preserving the significant improvement of postoperative outcomes.
前言:本研究旨在评价经尿道前列腺内麻醉(TUIA)下使用Schelin导管(SC)和sedo镇痛的钬激光前列腺摘除(HoLEP)患者的可行性和安全性。材料和方法:我们回顾性分析了2023年11月至2024年5月在TUIA下使用SC的良性前列腺阻塞候选HoLEP患者的资料。结果:共纳入50例患者,中位年龄67岁;ASA≥3.2的占14%,接受抗凝和抗血小板药物治疗的占2%,接受抗凝和抗血小板药物治疗的占22%;60%接受α受体阻滞剂治疗,22%同时接受α受体阻滞剂和5α-还原酶抑制剂治疗;18%的患者采用留置导尿管。术前国际前列腺症状评分中位数(IPSS)和生活质量中位数(IPSS- qol)分别为16 (IQR: 11-21)和4 (IQR: 4-6), Qmax中位数为10 mL/sec (IQR: 3-19),空隙后残留中位数(PVR)为79 mL (IQR: 0-500)。前列腺体积中位数为50 mL (IQR 41-70 cc)。术前前列腺特异性抗原(PSA)中位数为1,70 (IQR 1,1-2,95)。10%的患者前列腺体积≥80ml。中位去核时间为13.6分钟(IQR 11,15-21,45),中位分块时间为8.3分钟(IQR 4,2-10,8)。中位去核重量为33 g (IQR 19,50-50)。手术前、SC插入时、去核时、分拆时、术后2小时、第1天和第2天的中位疼痛数值评定量表分别为1(0-3)、5(2-6)、5(3-7)、7(5-10)、2(1-4)、2(1-4)和3(2-6)。在去核过程中,10%需要开始靶控输注异丙酚。分拆过程中,病人需要开始注射异丙酚。100%患者2天内拔管,48小时内全部出院。IPSS、IPSS- qol、Qmax和PVR在3个月时均有显著改善。结论:中、小前列腺体积HoLEP的TUIA联合sedo镇痛具有良好的疼痛控制,保留了术后疗效的显著改善。
{"title":"Feasibility and Safety of Holmium Laser Enucleation of the Prostate for Small to Medium Volumes Under Local Anesthesia with the Schelin Catheter and Sedoanalgesia: Results from a Single-Center Pilot Study.","authors":"Gianna Pace, Daniele Romagnoli, Alessandro Del Rosso, Stefano Vidiri, Orest Xhafka, Gianluca Brunetti","doi":"10.1177/08927790251414138","DOIUrl":"https://doi.org/10.1177/08927790251414138","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the feasibility and safety of patients undergoing holmium laser enucleation of prostate (HoLEP), under transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter (SC) and sedoanalgesia.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed data of patients affected by benign prostatic obstruction candidate to HoLEP under TUIA using SC, from November 2023 to May 2024.</p><p><strong>Results: </strong>A total of 50 patients were enrolled, median age 67 years; 14% were ASA ≥ 3, 2% and 22% had anticoagulation and antiplatelet drug therapy; 60% received alpha blockers, and 22% had both alpha blockers and 5α-reductase inhibitors; and 18% with an indwelling catheter. Preoperative median International Prostate Symptom Score (IPSS) and IPSS-quality of life (IPSS-QoL) were 16 (IQR: 11-21) and 4 (IQR: 4-6), median Qmax 10 mL/sec (IQR 3-19), median postvoid residual (PVR) 79 mL (IQR: 0-500). The median prostate volume was 50 mL (IQR 41-70 cc). Median preoperative Prostate Specific Antigen (PSA) was 1,70 (IQR 1,1-2,95). A prostate volume ≥ 80 mL was present in 10% of patients. The median enucleation time was 13,6 minutes (IQR 11,15-21,45) and the median morcellation time was 8,3 minutes (IQR 4,2-10,8). The median enucleated weight was 33 g (IQR 19,50-50). Median pain numeric rating scale before surgical procedure, at SC insertion, during enucleation, during morcellation, 2-hours postoperatively, on day 1 and 2 were 1 (0-3), 5 (2-6), 5 (3-7), 7 (5-10), 2 (1-4), 2 (1-4), and 3 (2-6). During enucleation, 10% required to start the target-controlled infusion with propofol. During morcellation, a half needs to get started propofol administration. The catheter was removed within 2 days in 100% of patients, and all were discharged within 48 hours. IPSS, IPSS-QoL, Qmax, and PVR showed significant improvement at 3 months.</p><p><strong>Conclusions: </strong>TUIA with sedoanalgesia in HoLEP of small/medium prostate volume offers good pain control, preserving the significant improvement of postoperative outcomes.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":"40 2","pages":"212-218"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-10-29DOI: 10.1177/08927790251390880
Luke Drew, Daniel Jhang, Kirulus Amin, Jersey-Kate Castillo, Ala'a Farkouh, Evan Seibly, Antoin Douglawi, Martin Hofmann, Forrest Jellison, Brian Hu, D Duane Baldwin, Herbert Ruckle, Muhannad Alsyouf
Introduction: Prophylactic ureteral catheterization (PUC) is routinely performed during non-urologic procedures to avoid iatrogenic ureteral injury. However, evidence of its benefit is conflicting, as data suggest that the rate of ureteral injury is unchanged and there is lack of data reporting associated complications. The purpose of this study was to evaluate the outcomes of routine PUC in non-urologic surgeries.
Methods: All consecutive patients who underwent PUC during non-urologic procedures between January 2019 and March 2024 were reviewed. Demographic, clinical, and perioperative characteristics, including ureteral injury rates, were reviewed. Complications within 90 days were divided into low-grade (urinary tract infection [UTI], gross hematuria, and flank pain) and high-grade (new or worsening hydronephrosis and need for nephrostomy or indwelling stent). Logistic regression was performed to identify predictors of PUC-related complications.
Results: Among 233 patients, 63.5% were female. Median age and body mass index were 57 years and 28, respectively. Patient history included neoadjuvant chemotherapy in 54 (23%), pelvic radiation in 43 (18%), and pelvic surgery in 119 (51%). Surgery types included colorectal (75.1%), gynecological (14.2%), or both (10.7%). A total of 101 urologic complications affected 43% of patients, including UTI (22.3%), gross hematuria (24.4%), flank pain (10.7%), new/worsening hydronephrosis (9.9%), and need for nephrostomy tube/stent (1.3%). Intraoperative ureteral injury rate was 3.9%. On multivariate analysis, prior pelvic radiation was significantly associated with the occurrence of high-grade complications (odds ratio 3.29, 95% CI 1.04, 10.43).
Conclusion: PUC during non-urologic procedures is associated with a small but significant risk of urologic complications and does not eliminate the risk of ureteral injury. Prior pelvic radiation is a significant risk factor for PUC-related complications.
导读:预防性输尿管置管术(PUC)在非泌尿外科手术中常规进行,以避免医源性输尿管损伤。然而,其益处的证据是相互矛盾的,因为数据表明输尿管损伤率不变,缺乏相关并发症的数据报告。本研究的目的是评估常规PUC在非泌尿外科手术中的效果。方法:回顾2019年1月至2024年3月期间所有在非泌尿外科手术中连续接受PUC的患者。回顾了人口统计学、临床和围手术期特征,包括输尿管损伤率。90天内的并发症分为低级别(尿路感染[UTI]、肉眼血尿、侧腹疼痛)和高级别(新发或恶化的肾积水,需要肾造口或留置支架)。采用逻辑回归来确定前列腺癌相关并发症的预测因素。结果:233例患者中,女性占63.5%。中位年龄和体重指数分别为57岁和28岁。患者病史包括新辅助化疗54例(23%),盆腔放疗43例(18%),盆腔手术119例(51%)。手术类型包括结直肠(75.1%)、妇科(14.2%)或两者兼而有之(10.7%)。共有101个泌尿系统并发症影响了43%的患者,包括尿路感染(22.3%)、血尿(24.4%)、侧腹疼痛(10.7%)、新发/恶化的肾积水(9.9%)和需要肾造口管/支架(1.3%)。术中输尿管损伤率为3.9%。在多变量分析中,既往盆腔放疗与高级别并发症的发生显著相关(优势比3.29,95% CI 1.04, 10.43)。结论:非泌尿外科手术期间PUC与泌尿外科并发症的风险小但显著相关,并不能消除输尿管损伤的风险。既往盆腔放疗是前列腺癌相关并发症的重要危险因素。
{"title":"Outcomes of Prophylactic Ureteral Catheterization for Ureteral Identification During Non-Urologic Surgery.","authors":"Luke Drew, Daniel Jhang, Kirulus Amin, Jersey-Kate Castillo, Ala'a Farkouh, Evan Seibly, Antoin Douglawi, Martin Hofmann, Forrest Jellison, Brian Hu, D Duane Baldwin, Herbert Ruckle, Muhannad Alsyouf","doi":"10.1177/08927790251390880","DOIUrl":"10.1177/08927790251390880","url":null,"abstract":"<p><strong>Introduction: </strong>Prophylactic ureteral catheterization (PUC) is routinely performed during non-urologic procedures to avoid iatrogenic ureteral injury. However, evidence of its benefit is conflicting, as data suggest that the rate of ureteral injury is unchanged and there is lack of data reporting associated complications. The purpose of this study was to evaluate the outcomes of routine PUC in non-urologic surgeries.</p><p><strong>Methods: </strong>All consecutive patients who underwent PUC during non-urologic procedures between January 2019 and March 2024 were reviewed. Demographic, clinical, and perioperative characteristics, including ureteral injury rates, were reviewed. Complications within 90 days were divided into low-grade (urinary tract infection [UTI], gross hematuria, and flank pain) and high-grade (new or worsening hydronephrosis and need for nephrostomy or indwelling stent). Logistic regression was performed to identify predictors of PUC-related complications.</p><p><strong>Results: </strong>Among 233 patients, 63.5% were female. Median age and body mass index were 57 years and 28, respectively. Patient history included neoadjuvant chemotherapy in 54 (23%), pelvic radiation in 43 (18%), and pelvic surgery in 119 (51%). Surgery types included colorectal (75.1%), gynecological (14.2%), or both (10.7%). A total of 101 urologic complications affected 43% of patients, including UTI (22.3%), gross hematuria (24.4%), flank pain (10.7%), new/worsening hydronephrosis (9.9%), and need for nephrostomy tube/stent (1.3%). Intraoperative ureteral injury rate was 3.9%. On multivariate analysis, prior pelvic radiation was significantly associated with the occurrence of high-grade complications (odds ratio 3.29, 95% CI 1.04, 10.43).</p><p><strong>Conclusion: </strong>PUC during non-urologic procedures is associated with a small but significant risk of urologic complications and does not eliminate the risk of ureteral injury. Prior pelvic radiation is a significant risk factor for PUC-related complications.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"233-238"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145409259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-23DOI: 10.1177/08927790251408826
Yuyang Yuan, Lizhi Zhou, Jiaqing Yang, Fuchun Zheng, Xinchang Zou, Xiaoqiang Liu, Luyao Chen, Jieping Hu, Bin Fu
Objective: To develop an interpretable machine learning (ML) model for predicting surgical outcomes in renal hilar tumors and propose a hilar-specific anatomical nephrometry scoring system.
Methods: A total of 414 patients with renal hilar tumors who underwent robot-assisted partial nephrectomy (RAPN) were included in this study, comprising 304 patients from the First Affiliated Hospital of Nanchang University and 110 patients from the Second Affiliated Hospital of Nanchang University, which served as the external validation cohort. To identify predictors of trifecta achievement, we used least absolute shrinkage and selection operator regression and the Boruta algorithm, followed by multivariate logistic regression to identify independent factors. Five ML models were developed and evaluated using receiver operating characteristic curves, calibration plots, decision curve analysis, and precision-recall curves. The generalizability of the model was further validated in external cohort. Finally, we used SHapley Additive exPlanations (SHAP) to interpret the contribution of each predictor and enhance the model's explainability. Furthermore, based on anatomical features identified through logistic regression, we developed a modified nephrometry scoring system and compared its risk stratification performance with the traditional R.E.N.A.L. (i.e., Radius, Exophytic or endophytic, Nearness, Anterior or posterior, and Location) scoring system.
Results: Among the 304 patients in the primary cohort, 168 achieved trifecta outcomes. Eight variables were incorporated into the predictive model, with logistic regression model ultimately being selected as the optimal predictive model. It showed robust predictive performance in internal and external validation. SHAP methods identified surgeon, classification of hilar tumor, and radius as the three most significant predictive variables. Compared with the traditional R.E.N.A.L. score, the modified R.E.N.A.L. score demonstrated superior stratification ability for operation time, change in serum creatinine, change in estimated glomerular filtration rate, and trifecta achievement.
Conclusion: The interpretable ML model accurately predicts trifecta in RAPN for hilar tumors. The modified R.E.N.A.L. score provides refined anatomical stratification and facilitates individualized surgical planning.
{"title":"Development and Validation of Predictive Models for Trifecta Achievement in Robot-Assisted Partial Nephrectomy for Renal Hilar Tumors: Preliminary Application of the Modified R.E.N.A.L. Score.","authors":"Yuyang Yuan, Lizhi Zhou, Jiaqing Yang, Fuchun Zheng, Xinchang Zou, Xiaoqiang Liu, Luyao Chen, Jieping Hu, Bin Fu","doi":"10.1177/08927790251408826","DOIUrl":"https://doi.org/10.1177/08927790251408826","url":null,"abstract":"<p><strong>Objective: </strong>To develop an interpretable machine learning (ML) model for predicting surgical outcomes in renal hilar tumors and propose a hilar-specific anatomical nephrometry scoring system.</p><p><strong>Methods: </strong>A total of 414 patients with renal hilar tumors who underwent robot-assisted partial nephrectomy (RAPN) were included in this study, comprising 304 patients from the First Affiliated Hospital of Nanchang University and 110 patients from the Second Affiliated Hospital of Nanchang University, which served as the external validation cohort. To identify predictors of trifecta achievement, we used least absolute shrinkage and selection operator regression and the Boruta algorithm, followed by multivariate logistic regression to identify independent factors. Five ML models were developed and evaluated using receiver operating characteristic curves, calibration plots, decision curve analysis, and precision-recall curves. The generalizability of the model was further validated in external cohort. Finally, we used SHapley Additive exPlanations (SHAP) to interpret the contribution of each predictor and enhance the model's explainability. Furthermore, based on anatomical features identified through logistic regression, we developed a modified nephrometry scoring system and compared its risk stratification performance with the traditional R.E.N.A.L. (i.e., Radius, Exophytic or endophytic, Nearness, Anterior or posterior, and Location) scoring system.</p><p><strong>Results: </strong>Among the 304 patients in the primary cohort, 168 achieved trifecta outcomes. Eight variables were incorporated into the predictive model, with logistic regression model ultimately being selected as the optimal predictive model. It showed robust predictive performance in internal and external validation. SHAP methods identified surgeon, classification of hilar tumor, and radius as the three most significant predictive variables. Compared with the traditional R.E.N.A.L. score, the modified R.E.N.A.L. score demonstrated superior stratification ability for operation time, change in serum creatinine, change in estimated glomerular filtration rate, and trifecta achievement.</p><p><strong>Conclusion: </strong>The interpretable ML model accurately predicts trifecta in RAPN for hilar tumors. The modified R.E.N.A.L. score provides refined anatomical stratification and facilitates individualized surgical planning.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":"40 2","pages":"188-204"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-14DOI: 10.1177/08927790251394381
Stefanie M Croghan, Nnaemeka Eli, Angus Luk, Christoph Schregel, Matthew Shaw, Rob Williams, Alistair Rogers
Urologists face a significant challenge when presented with cases in which complete, yet reversible, urinary diversion is desirable. With multidisciplinary collaboration, we have used a novel technique involving the antegrade deployment of distally-ligated covered metal (Allium®) ureteral stents, achieving ureteral occlusion and complete urinary diversion via nephrostomy tubes. We have used this technique, with good early results, in complex cases, including that of a young male patient with complex pelvic injuries after polytrauma and a female patient with a malignant vesicovaginal fistula, neither of whom were candidates for definitive surgical reconstruction or diversion at the time of treatment. We describe our experience, which we believe may be of interest to urologists and interventional radiologists managing similarly challenging cases.
{"title":"Novel Bilateral Ureteral Occlusion with Modified Expandable Metal Stents to Achieve Complete but Reversible Urinary Diversion.","authors":"Stefanie M Croghan, Nnaemeka Eli, Angus Luk, Christoph Schregel, Matthew Shaw, Rob Williams, Alistair Rogers","doi":"10.1177/08927790251394381","DOIUrl":"10.1177/08927790251394381","url":null,"abstract":"<p><p>Urologists face a significant challenge when presented with cases in which complete, yet reversible, urinary diversion is desirable. With multidisciplinary collaboration, we have used a novel technique involving the antegrade deployment of distally-ligated covered metal (Allium®) ureteral stents, achieving ureteral occlusion and complete urinary diversion via nephrostomy tubes. We have used this technique, with good early results, in complex cases, including that of a young male patient with complex pelvic injuries after polytrauma and a female patient with a malignant vesicovaginal fistula, neither of whom were candidates for definitive surgical reconstruction or diversion at the time of treatment. We describe our experience, which we believe may be of interest to urologists and interventional radiologists managing similarly challenging cases.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"79-83"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-24DOI: 10.1177/08927790251388465
Orel Hemo, Asaf Shvero, Dorit E Zilberman, Zohar A Dotan, Nir Kleinmann
Purpose: Percutaneous nephrolithotomy (PCNL) is the gold standard for treating kidney stones >20 mm because of its superior stone-free rates (SFR). However, high-power holmium lasers may challenge this standard. This study evaluates the feasibility, safety, and efficacy of high-power holmium laser retrograde intrarenal surgery (RIRS) for the treatment of kidney stones >20 mm.
Methods: We conducted a retrospective analysis of patients with kidney stones >20 mm treated with either 80W- or 120 W holmium laser RIRS between January 2020 and August 2024. Clinical, intraoperative, and postoperative data were collected. Outcomes included SFR, operative time, complications, and hospital stay. Comparisons between the older-generation (80 W) and newer-generation (120 W) systems were performed using the Mann-Whitney U test and chi-square test, and multivariable analyses identified predictors of non-stone-free status.
Results: A total of 118 patients were included: 31 in the older-generation (80 W) group and 87 in the newer-generation (120 W) group. RIRS using the newer-generation 120 W laser was associated with a shorter operative time (66 vs 79 minutes, p < 0.001) and higher SFR at 5 weeks (82.7% vs 58.1%, p = 0.006), 6 months (92% vs 64.5%, p < 0.001), and 1 year (96.5% vs 83.8%, p = 0.016) postoperative evaluations. Complication rates did not differ significantly between groups (5.7% vs 3.2%, p = 0.208). In multivariable analysis, the use of older-generation 80 W laser was an independent predictor of non-stone-free status at both the first (OR 4.4, p = 0.004) and second (OR 8.8, p = 0.001) follow-up visits.
Conclusions: Treatment of renal stones larger than 2 cm with the newer-generation 120 W Ho:YAG laser is effective, with higher SFR rate and shorter operative time, compared to the older-generation 80 W Ho:YAG laser.
目的:经皮肾镜取石术(PCNL)因其具有较高的无结石率(SFR)而成为治疗直径20毫米肾结石的金标准。然而,高功率钬激光器可能会挑战这一标准。本研究评估高功率钬激光逆行肾内手术(RIRS)治疗肾结石bb0 ~ 20mm的可行性、安全性和有效性。方法:我们对2020年1月至2024年8月期间接受80W或120w钬激光RIRS治疗的肾结石患者进行了回顾性分析。收集临床、术中、术后资料。结果包括SFR、手术时间、并发症和住院时间。使用Mann-Whitney U检验和卡方检验对老一代(80 W)和新一代(120 W)系统进行比较,并通过多变量分析确定非结石状态的预测因子。结果:共纳入118例患者:老一代(80 W)组31例,新一代(120 W)组87例。使用新一代120w激光的RIRS在术后5周(82.7% vs 58.1%, p = 0.006)、6个月(92% vs 64.5%, p < 0.001)和1年(96.5% vs 83.8%, p = 0.016)的评估中与较短的手术时间(66 vs 79分钟,p < 0.001)和较高的SFR相关。两组间并发症发生率无显著差异(5.7% vs 3.2%, p = 0.208)。在多变量分析中,使用老一代80 W激光是第一次(OR 4.4, p = 0.004)和第二次(OR 8.8, p = 0.001)随访时非结石状态的独立预测因子。结论:与老一代80 W Ho:YAG激光相比,新一代120 W Ho:YAG激光治疗大于2 cm的肾结石具有更高的SFR率和更短的手术时间。
{"title":"High-Power Retrograde Intrarenal Surgery Holmium Laser Lithotripsy for Kidney Stones Larger Than 20 mm.","authors":"Orel Hemo, Asaf Shvero, Dorit E Zilberman, Zohar A Dotan, Nir Kleinmann","doi":"10.1177/08927790251388465","DOIUrl":"10.1177/08927790251388465","url":null,"abstract":"<p><strong>Purpose: </strong>Percutaneous nephrolithotomy (PCNL) is the gold standard for treating kidney stones >20 mm because of its superior stone-free rates (SFR). However, high-power holmium lasers may challenge this standard. This study evaluates the feasibility, safety, and efficacy of high-power holmium laser retrograde intrarenal surgery (RIRS) for the treatment of kidney stones >20 mm.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with kidney stones >20 mm treated with either 80W- or 120 W holmium laser RIRS between January 2020 and August 2024. Clinical, intraoperative, and postoperative data were collected. Outcomes included SFR, operative time, complications, and hospital stay. Comparisons between the older-generation (80 W) and newer-generation (120 W) systems were performed using the Mann-Whitney <i>U</i> test and chi-square test, and multivariable analyses identified predictors of non-stone-free status.</p><p><strong>Results: </strong>A total of 118 patients were included: 31 in the older-generation (80 W) group and 87 in the newer-generation (120 W) group. RIRS using the newer-generation 120 W laser was associated with a shorter operative time (66 <i>vs</i> 79 minutes, <i>p</i> < 0.001) and higher SFR at 5 weeks (82.7% <i>vs</i> 58.1%, p = 0.006), 6 months (92% <i>vs</i> 64.5%, <i>p</i> < 0.001), and 1 year (96.5% <i>vs</i> 83.8%, <i>p</i> = 0.016) postoperative evaluations. Complication rates did not differ significantly between groups (5.7% <i>vs</i> 3.2%, <i>p</i> = 0.208). In multivariable analysis, the use of older-generation 80 W laser was an independent predictor of non-stone-free status at both the first (OR 4.4, <i>p</i> = 0.004) and second (OR 8.8, <i>p</i> = 0.001) follow-up visits.</p><p><strong>Conclusions: </strong>Treatment of renal stones larger than 2 cm with the newer-generation 120 W Ho:YAG laser is effective, with higher SFR rate and shorter operative time, compared to the older-generation 80 W Ho:YAG laser.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}